The Galleri test, a pioneering blood test developed by the American firm Grail, has shown promising results in detecting over 50 types of cancer before symptoms manifest. According to a trial supported by the NHS, the test could prevent one in five late-stage cancer diagnoses, potentially saving up to 30,000 lives annually in the UK. The trial, which involved more than 142,000 adults aged 50 to 77, revealed that nearly 1% tested positive, with 52% of these cases later confirmed as cancer. Notably, the test demonstrated a significant reduction in late-stage diagnoses, with stage 4 oesophageal cancer cases falling by over 57%. The results are expected to shift cancer detection from reactive to proactive, allowing for earlier treatment options. Experts emphasize the need for increased investment in diagnostics to integrate this test into existing NHS pathways effectively. The trial's findings will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting, highlighting the potential for the Galleri test to transform cancer care in the UK.